In conclusion, although PD-1/PD-L1 blockades have a bright future in the field of cancer immunotherapy, nanoplatforms targeting the PD-1/PD-L1 pathway still need to move forward to eventually improve the therapeutic outcomes in patients. The gene discussed is CD274; the disease is cancer.